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Abstract
Complex reduced polyketides represent the largest class of natural products that have applications in medicine, agriculture, 
and animal health. This structurally diverse class of compounds shares a common methodology of biosynthesis employing 
modular enzyme systems called polyketide synthases (PKSs). The modules are composed of enzymatic domains that share 
sequence and functional similarity across all known PKSs. We have used the nomenclature of synthetic biology to classify 
the enzymatic domains and modules as parts and devices, respectively, and have generated detailed lists of both. In addition, 
we describe the chassis (hosts) that are used to assemble, express, and engineer the parts and devices to produce polyketides. 
We describe a recently developed software tool to design PKS system and provide an example of its use. Finally, we provide 
perspectives of what needs to be accomplished to fully realize the potential that synthetic biology approaches bring to this 
class of molecules.
Keywords Biosynthesis · Cheminformatics · Natural products · Novel chemicals · Refactoring · Streptomyces
Introduction
Synthetic biology is an emerging discipline that combines 
the fields of biology, biotechnology and engineering for the 
design and construction of new biological parts, devices, and 
systems, as well as the re-design of existing natural biologi-
cal systems, all for useful purposes. To make the engineering 
of biology faster, more reliable, and more reproducible, syn-
thetic biologists have developed a framework for engineer-
ing biology that is similar to other engineering disciplines, 
including standardized, off the shelf parts (e.g., genes) with 
standardized connections that could be used and reused in 
the construction of devices and larger systems. For example, 
a computer can be assembled from standardized parts and 
devices (sound cards, processors, operating systems, hard 
drives, etc.) available from many vendors; devices such as 
monitors, scanners, printers, etc., are connected to the com-
puter through a standard port.
Synthetic biology has numerous applications: it can be 
used for the construction of proteins that can serve as new 
vaccines, or new biochemical pathways synthesizing small 
molecules that can serve as pharmaceuticals, chemicals (sol-
vents, adhesives, food flavorings, cosmetics, etc.), or bio-
fuels, plant and animal growth stimulators or insecticides. 
Additional applications include the generation of new bio-
sensors for early detection of medical conditions, or to detect 
environmental pollution. The hosts used for production of 
new proteins, small molecules, or biosensors were desig-
nated as chassis. Synthetic biology also includes the direct 
engineering of chassis, as well as the technologies such as 
CRISPR/Cas9 to make chassis easier to engineer.
Reduced polyketides are a sub-class of natural products 
that have a variety of medical, veterinary, and agricultural 
applications. Examples, shown in Fig. 1, include the US 
Food and Drug Administration (FDA)-approved antibacte-
rial agents erythromycin, fidaxomicin, rifamycin and tylosin; 
Satoshi Yuzawa and Tyler W. H. Backman contributed equally.
 * Leonard Katz 
 katzl@berkeley.edu
1 Biological Systems and Engineering Division, Lawrence 
Berkeley National Laboratory, Berkeley, CA 94720, USA
2 Joint BioEnergy Institute, Emeryville, CA 94608, USA
3 QB3 Institute, University of California, Berkeley, CA 94720, 
USA
4 Department of Bioengineering, University of California, 
Berkeley, CA 94720, USA
5 Department of Chemical and Biomolecular Engineering, 
University of California, Berkeley, CA 94720, USA
6 Novo Nordisk Foundation Center for Biosustainability, 
Technical University of Denmark, Hørsholm, Denmark
 Journal of Industrial Microbiology & Biotechnology
1 3
the antifungal agent amphotericin; the immunosuppressive 
agents rapamycin and tacrolimus; the cholesterol lowering 
agent lovastatin; the anthelmintic agent avermectin; the 
insecticide spinsosad; and monensin, a growth promotant 
for ruminants and coccidiostat in poultry. Curacin, disco-
dermolide, epothilone, geldanamycin, and salinosporamide 
have anti-cancer properties and are in clinical trials. With 
the exception of lovastatin, which is produced by the fungus 
Aspergillus terreus, as well as a number of higher plants, all 
of the compounds shown in Fig. 1 are produced by bacteria, 
in particular members of the mycelia-forming family called 
actinomycetes that includes the most common genus Strep-
tomyces, as well as the genera Dactylosporangium, and Sac-
charopolyspora, among others. Many members of the myxo-
bacteria family also produce polyketides (e.g., epothilone, 
disorazole). Curacin is made in the cyanobacterium Lyngbya 
majuscula. Discodermolide was isolated from a sponge, but 
it is believed that it is produced by a symbiotic bacterium. 
Although these compounds do not resemble each other, and 
have different biological targets, they are all made by a class 
of enzymes known as modular polyketide synthases (PKSs), 
which produce the polyketide backbones. An example of a 
modular PKS is 6-deoxyerythronolide B synthase (DEBS), 
which produces 6-deoxyerythronolide B (6-dEB), the pol-
yketide backbone of erythromycin (Fig. 2), which undergoes 
post-polyketide processing (glycosidation, hydroxylation, 
O-methylation) to generate the final product erythromycin. 
Some of the other compounds shown in Fig. 1 (e.g., chal-
comycin, fidaxomicin, methymycin, and tylosin) undergo 
similar post-polyketide processing, whereas others, such 
as splenocin and geldanamycin undergo acylation or car-
bamoylation, respectively. Discodermolide and epothilone 
undergo little or no further elaboration. Some polyketides 
are connected to an amino acid or amino acid derivative 
(e.g., epothilone, rapamycin, tacrolimus, and lipomycin) 
via a linked non-ribosomal peptide synthetase (NRPS). The 
polyketide backbone of monensin reforms into a polyether, 
whereas part of the backbone of the reveromycin assumes a 
spiroketal configuration.
Although great structural diversity is observed for pol-
yketides, they share, as outlined below, an overarching simi-
larity in their biosynthesis. This has drawn the attention of 
a variety of scientists interested in understanding the fun-
damental basis of how these molecules are made and the 
common and differentiating features of their biosynthesis. In 
addition, their medical and industrial importance has drawn 
the interest of pharmaceutical and industrial companies who 
desire to apply genetic approaches to change the structures 
of polyketides to improve their properties or generate chemi-
cal diversity.
This paper is intended for people interested in synthetic 
biology who may not be familiar with polyketides and 
PKSs. It is, therefore, not intended to be comprehensive 
with respect to the detailed enzymology of PKS or present 
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Fig. 1  Structures of natural polyketides. The parts of the compounds determined by the corresponding polyketide synthase are highlighted in 
dark
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a complete review of the genetic engineering of PKS genes 
that has been reported over the past 27 years. For that, the 
reader is directed to a number of recent reviews [3, 4, 21, 38, 
44]. Rather, we attempt to show here that nature has devised 
a near perfect synthetic biology system of composable parts 
and devices in PKSs which can be assigned specific nomen-
clature according to function. We believe that this nomen-
clature will be interesting to synthetic biologists, as well as 
people who work with polyketides and PKSs, and useful for 
those interested in recomposing parts and devices to create 
new polyketides. We present an overview of work done in 
this area and discuss what needs to be understood that will 
make PKSs easier to engineer.
Overview of modular PKS enzymology
As can be seen in Fig. 2, 6-dEB is built by the stepwise 
condensation of propionyl-CoA and 6 molecules of meth-
ylmalonyl-CoA in a manner similar to the biosynthesis 
of fatty acids, which are produced by fatty acid synthases 
(FASs). However, unlike FASs [5], which use a single 
set of enzymes or enzymatic domains for all elongation 
steps, each polyketide chain elongation step is carried out 
by a discrete set of catalytic domains, which is defined 
as an extension module. Other modular PKSs also use 
acyl-CoAs or carboxyacyl-CoAs as substrates. The num-
ber of modules in a given PKS determines the size of the 
resultant polyketide produced, and the specific carboxy-
acyl-CoAs employed, which are selected by the modules 
themselves, determine the overall structure. DEBS has 6 
extension modules that use methylmalonyl-CoA, in addi-
tion to the N-terminal loading module and the C-terminal 
off-loading domain, which accounts for the 14-membered 
macrolactone ring and a methyl group at every other posi-
tion in the ring. In contrast, the fidaxomicin PKS, which, 
like erythromycin, also starts its synthesis with propionyl-
CoA, has 8 extension modules, and uses malonyl-CoA in 
the first, sixth, and seventh extensions, methylmalonyl-
CoA, in the second, third, fifth, and eighth extensions, 
and ethylmalonyl-CoA in the fourth extension, yielding 
an 18-membered macrolactone (Fig. 1). Each module also 
controls the reduction state of the corresponding elongated 
polyketide intermediate by having a specific set of reduc-
tase domains, whereas FASs exclusively provide only the 
fully reduced forms of their products. In addition, modular 
PKSs can control the stereochemistry at each chiral center 
as described below. Hence, the modular nature of the PKSs 
not only accounts for the thousands of diverse natural pol-
yketide structures, but also offers a wealth of engineering 
opportunities for the production of novel compounds.
Fig. 2  Organization of the 6-deoxyerythronolide B synthase (DEBS) 
and structure of its product, 6-deoxyerythronolide B (6dEB). Step-
wise growth of the polyketide chain of the polyketide chain is shown 
attached to the ACP domain of each module after full elaboration, 
including stereochemistry, by modular functions. Modules are labeled 
Load through Module 6 and are delineated by solid black lines. The 
proteins comprising DEBS are shown by arrows. The atoms labeled 1 
and 13 in the acyl chain attached to module 6 undergo a lactonization 
reaction conducted by the TE domain to result in the production of 
the macrolactone 6-dEB, which undergoes further biochemical pro-
cessing (not shown) to generate erythromycin (Fig. 1). Abbreviations: 
ACP, acyl carrier protein; AT, acyltransferase; DH, dehydratase; ER, 
enoyltransferase; KR, β-ketoreductase; KS, β-acyl ACP synthase; TE, 
thioesterase
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Polyketide chain elongation is catalyzed by three dif-
ferent catalytic domains: a ketosynthase (KS) domain, an 
acyltransferase (AT) domain, and an acyl carrier protein 
(ACP) domain where the AT domain determines the specific 
carboxyacyl-CoA incorporated into the growing polyketide 
chain, and then transfers it to the ACP in the same module. 
The KS domain then catalyzes decarboxylative C–C bond 
formation between the growing polyketide chain and the 
extender unit on the ACP. Modular PKSs are categorized 
into cis- and trans-AT (or AT-less) modular PKS systems. 
In the trans-AT type, each module lacks an AT domain and 
instead receives its substrate, by one or more free-stand-
ing ATs. For example, disorazole (Fig. 1) is produced by 
a trans-AT PKS. Although most of the free-standing ATs 
thus far identified are specific for malonyl-, methylmalonyl-, 
or ethylmalonyl-CoA [17], over 20 different malonyl-CoA 
analogs have been found to be incorporated into naturally 
occurring polyketides by cis-AT PKSs [46]. These analogs 
include short to medium-chain alkylmalonyl-CoAs, halo-
genated malonyl-CoAs, and benzylmalonyl-CoA (Fig. 3). 
Examples of compounds that contain side-chains in the pol-
yketide backbone that are larger than a simple methyl group 
in Fig. 1 include tylosin and monensin (ethyl), rapamycin 
(methoxy), tacrolimus (methoxy and allyl), reveromycin 
(butyl, pentyl, isopentyl, or hexyl), splenomycin (benzyl), 
and salinosporamide (chloro-, fluoro-, or bromoethyl), all of 
which are introduced as malonyl-CoA or malonyl-ACP ana-
logs by their corresponding cis-AT domains in their respec-
tive PKSs. In addition, there are a number of AT domains 
that can employ more than a single derivative of malonyl-
CoA as substrate for incorporation, such as the AT domain 
of module 4 (AT4) of the epothilone PKS, which can use 
either malonyl- or methylmalonyl-CoA, the AT5 domain 
of the monensin PKS, which incorporates either methyl-
malonyl- or ethylmalonyl-CoA, and the AT5 domain of the 
reveromycin PKS which can utilize four different alkylated 
malonyl-CoAs as substrates. The DEBS AT domains are 
known to incorporate only the (2S)-enantiomer of methyl-
malonyl-CoA [27] and the subsequent KS-catalyzed con-
densation reactions generate (2R)-2-methyl-3-ketoacyl-ACP 
intermediates, the opposite stereochemical orientation [45]. 
It is also thought, but not yet proven, that all AT domains 
that use alkylated malonyl-CoAs as substrates only use the 
corresponding 2S-enantiomers.
After each condensation step, the newly generated β-keto 
group is reduced by a ketoreductase (KR) domain if present 
in the module. DEBS contains a KR domain in modules 
1,2,4,5, and 6, and an inactive (reductase incompetent) KR 
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domain in module 3 (Fig. 2). Importantly, the stereochem-
istries of both β-hydroxyl- and α-alkyl side-chains in the 
nascent polyketide generated are controlled primarily by 
the individual KR domains of each PKS module [20]. KR 
domains are characterized based on their stereochemical out-
comes. A-type and B-type KRs generate the l-β-hydroxyl 
and d-β-hydroxyl groups, respectively. Each KR type can 
also control stereochemical orientations of α-substituents. 
This is important in all modules any acyl-CoA other than 
malonyl-CoA is introduced. A1- or B1-type KRs produce 
the d-α-substituent, and A2- or B2-type KRs produce l-α-
substituent. Finally, C1- or C2-type KRs are reductase-
incompetent but retain epimerase activity. The d/l system 
is not perfect but preferred over the R/S system because the 
assignment of R or S depends on the substituents present.
The trans or cis-double bonds within polyketides are gen-
erated by a dehydratase (DH) domain after KR-catalyzed 
reductions. DEBS has a DH domain in module 4. The syn-
coplanar water elimination reaction from a substrate pos-
sessing d-β-hydroxyl group generates a trans-double bond 
[43]. Thus, a trans-double bond typically results from a mod-
ule that contains B-type KR (B type KRs but not B2). In a 
module that contains an A-type KR, a cis-double bond can 
be generated. If a module further contains an enoyl reduc-
tase (ER) domain (e.g., DEBS module 4), stereoselective 
reduction of a trans-double bond possessing a α-substituent 
may occur [25]. ER domains are also characterized based 
on their stereochemical outcomes. L-type ERs generate 
l-α-substituents, and D-type ERs generate d-α-substituents. 
Recently, cryptic methyl group epimerase function of DH 
domains has also been reported [49].
 Both cis- and trans-AT PKS modules are known to har-
bor an integrated, S-adenosylmethionine-dependent C-meth-
yltransferase (MT) domain, which installs a methyl group to 
the α-carbon of β-keto polyketide intermediates. For exam-
ple, module 8 of the epothilone PKS (EPOS M8) carries a 
C-MT domain. Since the AT domain specifies methylmalo-
nyl-CoA, the gem-dimethyl group seen in epothilone is the 
result of a single methylation [37]. On the other hand, the 
C-MT domain of the PKS module for yersiniabactin biosyn-
thesis specifies dimethylation to produce the corresponding 
gem-dimethyl group [37]. Recently, C-MTs from trans-AT 
PKS systems have been shown to be stereospecific [50].
After the above-mentioned reactions, the elongated and 
reduced (if reduction domains are present) polyketide inter-
mediate is eventually translocated to the KS domain of the 
next module and similar reactions are repeated until the 
chain is fully elongated. Finally, thioesterase (TE) domains 
release products by cyclization or hydrolysis, thus generat-
ing lactones, lactams, and carboxylic acids [9]. TE domains 
are usually embedded into the last module of the PKSs but 
polyether-producing PKSs such as the nanchangmycin and 
monensin PKSs employ free-standing TEs to cleave the final 
intermediates [34, 42]. A few other less common termina-
tion mechanisms are also known. A tandem sulfotransferase 
(ST)-TE didomain yield terminal olefins, as found in the 
curacin PKS [7]. A reductive (R) domain produces alde-
hydes or alcohols, which are found in the coelimycin and 
myxalamid PKSs [14, 40].
The polyketide chain initiation event is catalyzed by 
domains, commonly called the loading module, preceding 
the first extension module. The most common loading mod-
ule consists of a condensation-incompetent KS domain (e.g., 
 KSQ, a Cys to Glu variant of a KS domain), an AT domain, 
and an ACP domain [31]. Here, the AT domain is specific 
for malonyl-CoA or methylmalonyl-CoA and generates 
acetyl or propionyl starter units, respectively, after a decar-
boxylation reaction by the  KSQ domain. On the other hand, 
loading modules consisting of AT-ACP didomains tends to 
show broader substrate specificity (the AT lacks the con-
served arginine residue, which stabilizes the acid moiety of 
malonyl- and methylmalonyl-CoA substrates). For example, 
as can been seen in the avermectin compounds shown in 
Fig. 1, the avermectin PKS can initiate polyketide biosyn-
thesis from either isobutyryl-CoA or 2-methylbutyryl-CoA 
[18]. This PKS is also known to incorporate a huge variety 
of synthetic starters that can be exogenously fed to a vari-
ant of the producing organism that lacks the ability to make 
the natural starter units [10]. Similarly, the lipomycin PKS 
has also been demonstrated to have broad substrate specific-
ity [52, 53]. On the other hand, the borrelidin PKS loading 
module was shown to be stereoselective and incorporate a 
carboxyacyl-CoA [15]. Another type of loading didomain 
is composed of a CoA-ligase (CoL) and an ACP domain, 
which usually activates a shikimic acid-derived cyclocar-
boxylic acid in an ATP-dependent manner and loads it onto 
the ACP. Some PKSs contain an additional domain between 
CoL and ACP domains, as found in the rapamycin PKS [39].
Synthetic biology of PKS: parts, devices, 
chassis
In synthetic biology jargon, the simplest unit of function 
is a part. For modular PKSs, the catalytic domains ACP, 
AT, DH, ER, KR, KS, C-MT, and TE, could be considered 
parts. A representative list of common PKS parts is shown 
in Table 1. AT parts are distinguishable on the basis of the 
substrate(s) that they utilize, e.g., malonyl-CoA, methylmal-
onyl-CoA, propionyl-CoA, etc. KR parts are distinguished 
on the basis of the stereochemistry generated at both the 
alkyl side chain (methyl, ethyl, etc.) at the α position, and the 
OH group at the β position. KR parts with stereochemistry 
unknown to the authors at the time of writing are represented 
by the code KRu. Other parts are represented in Table 1 
by a single code including ER (the current version of our 
 Journal of Industrial Microbiology & Biotechnology
1 3
software cannot distinguish different ER types), but it is pos-
sible that different KS domains will be found to have differ-
ent preferences for various acyl-ACPs. Similarly, subtypes 
of the other domains may also emerge.
A device consists of two or more parts, that has a function 
beyond that of the part. A simple device would be a gene, 
its promoter and a terminator, which can produce the cor-
responding protein. A more complicated device would be an 
operon consisting of several genes, along with a promoter 
and a terminator. In the context of PKS synthetic biology, 
PKS modules are considered devices. The simplest device 
in modular PKSs would consist of three parts: KS, AT and 
ACP; a complex device would contain KS, AT, DH, ER, 
KR, and ACP. A full PKS, which produces a functional pol-
yketide and composed of an assemblage of devices would 
be considered a system. Without reference to PKS systems, 
the term module has also been used to describe a reusable 
device, built from simpler parts. In the discussion of PKSs, 
we will use the terms module and device interchangeably. 
Table 2 shows a list of 56 devices that are components of 
known PKSs, along with their cognate parts. Devices are 
grouped by presence of reductive domains with DH-ER-
KR devices designated δ, DH-KR devices designated γ, KR 
devices designated β, and other devices designated α. The 
large number of devices is based on the variability of the AT 
and KR parts that comprise them. Figure 4 shows the struc-
tures of the growing or starting acyl chains attached to their 
cognate ACPs imparted by 25 devices selected from Table 2. 
It can be seen that devices α4 and α14 yield the structure, 
propionyl-ACP. In device α4, the ATp part (domain) directly 
loads propionyl-CoA to the ACP, whereas in device α14, 
the ATmm domain loads methylmalonyl-CoA onto the ACP 
and the KSQ domain subsequently decarboxylates it to leave 
propionyl-CoA.
Table 3 lists the PKS devices used for the production of 
15 of the polyketides shown in Fig. 1, excluding terminal 
Table 1  List of parts (domains) found in natural type I PKS systems and codes employed
Domain type Substrate/annotation Part code
Acyl carrier protein (ACP) ACP
Acyltransferase (AT) Allylmalonyl-CoA ATam
Chloroethylmalonyl-CoA ATcem
Trans-1,2-CPDA ATcpd
Ethylmalonyl-CoA ATem
Isobutyryl-CoA ATib
Malonyl-CoA ATm
Methylmalonyl-CoA ATmm
Methoxymalonyl-ACP ATmx
Propionyl-CoA ATp
Promiscuous: butylmalonyl-CoA or isopentylmalonyl-CoA or hexylmalo-
nyl-CoA
ATsp1
Promiscuous: ethylmalonyl-CoA or methylmalonyl-CoA ATsp2
Promiscuous: malonyl-CoA or methylmalonyl-CoA ATsp3
CoA-ligase (COL) Aminohydroxybenzoic acid COa
4,5-Dihydroxycyclohex-1-ene carboxylic acid COd
Dehydratase (DH) DH
Enoyl-ACP reductase (ER) ER
Ketoreductase (KR) Type A KRa
Type A1 KRa1
Type A2 KRa2
Type B KRb
Type B1 KRb1
Type B2 KRb2
Type C1 KRc1
Type C2 KRc2
Type unknown KRu
Ketoacyl ACP synthase (KS) KS
Ketoacyl ACP synthase loading (KSQ) KSQ
C-methyltransferase (MT) cMT
Journal of Industrial Microbiology & Biotechnology 
1 3
domains. The smallest and largest PKSs shown encode the 
backbones for methymycin and amphotericin B and con-
tain 6 and 19 devices, respectively. Many of the devices are 
common to two or more PKSs. Device γ3 is used in nine 
of the 12 PKSs shown, and is tandemly repeated in several 
PKSs including four times in lipomycin and six times in 
amphotericin. It is important to note that the PKS devices 
do not each have a single, unique sequence either at the 
protein or DNA level, although there is a high degree of 
similarity among the various representatives of each device. 
PKS devices are determined purely by function, namely the 
structure imparted onto the α and β carbons in the growing 
acyl chain during polyketide synthesis. The repetitive use of 
functionally identical modules to generate the large variety 
of polyketides produced in nature highlights them as natural 
reusable devices.
As mentioned above, many polyketides are generated in 
members of the genus Streptomyces. Streptomyces strains 
are likely the most promising chassis for forward engineer-
ing because they generally encode a substrate promiscuous 
phosphopantetheinyl transferase (PPTase) that is neces-
sary to functionalize heterologous PKS genes expressed in 
the host. PPTases are absent in the model microbial hosts 
Escherichia coli and Saccharomyces cerevisiae widely used 
in synthetic biology. Streptomyces hosts are also known to 
produce diverse acyl-CoAs and carboxyacyl-CoAs such 
as isobutyryl-CoA and methylmalonyl-CoA that are not 
naturally produced in E. coli and S. cerevisiae. Recently, 
approximately 200 native or synthetic promoters and ~ 200 
ribosomal binding sites were characterized in Streptomyces 
venezuelae, and some were also validated in two other Strep-
tomyces strains; their promoter strengths were highly cor-
related in the three chassis [1]. CRISPR/Cas9 systems have 
been developed for genome editing of several different Strep-
tomyces strains [26]. These systems enabled direct selec-
tion (via survival) for double homologous recombination, 
and were shown to shorten the time and effort required for 
genome engineering over the methodologies formerly used 
for gene replacement. For large gene insertions (> 5 kb), 
a number of actinophage integrase-based site-specific gene 
Table 2  Representative list of 
devices (modules) found in 
natural PKS systems and codes 
employed
List of parts from Table 1
Parts Device code Parts Device code
ATcpd, ACP α1 KS, ATmm, KRc2, ACP β15
ATib, ACP α2 KS, ATmm, KRu, ACP β16
ATmm, ACP α3 KS, ATmm, cMT, KRc1, ACP β17
ATp, ACP α4 KS, ATmx, KRa1, ACP β18
COa, ACP α5 KS, ATmx, KRb1, ACP β19
COd, ACP α6 KS, ATsp3, KRa, ACP β20
KS, ATam, ACP α7 KS, ATem, DH, KRb1, ACP γ1
KS, ATem, ACP α8 KS, ATm, DH, KRa, ACP γ2
KS, ATm, ACP α9 KS, ATm, DH, KRb, ACP γ3
KS, ATmm, ACP α10 KS, ATm, DH, KRu, ACP γ4
KSQ, ACP α11 KS, ATmm, DH, KRa1, ACP γ5
KSQ, ATib, ACP α12 KS, ATmm, DH, KRa2, ACP γ6
KSQ, ATm, ACP α13 KS, ATmm, DH, KRb1, ACP γ7
KSQ, ATmm, ACP α14 KS, ATmm, DH, KRc1, ACP γ8
KS, ATem, KRa1, ACP β1 KS, ATmm, DH, KRc2, ACP γ9
KS, ATem, KRa2, ACP β2 KS, ATmm, DH, KRu, ACP γ10
KS, ATem, KRb1, ACP β3 KS, ATmm, DH, cMT, KRc1, ACP γ11
KS, ATem, KRu, ACP β4 KS, ATmx, DH, KRb1, ACP γ12
KS, ATm, KRa, ACP β5 KS, ATsp2, DH, KRb1, ACP γ13
KS, ATm, KRb, ACP β6 KS, ATem, DH, ER, KRb1, ACP δ1
KS, ATm, KRu, ACP β7 KS, ATem, DH, ER, KRu, ACP δ2
KS, ATm, cMT, KRu, ACP β8 KS, ATm, DH, ER, KRa, ACP δ3
KS, ATmm, KRa, ACP β9 KS, ATm, DH, ER, KRb, ACP δ4
KS, ATmm, KRa1, ACP β10 KS, ATm, DH, ER, KRu, ACP δ5
KS, ATmm, KRa2, ACP β11 KS, ATmm, DH, ER, KRb1, ACP δ6
KS, ATmm, KRb1, ACP β12 KS, ATmm, DH, ER, KRc2, ACP δ7
KS, ATmm, KRb2, ACP β13 KS, ATmm, DH, ER, KRu, ACP δ8
KS, ATmm, KRc1, ACP β14 KS, ATmx, DH, ER, KRb1, ACP δ9
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Fig. 4  Structures, including stereochemistry, of the α and β positions (shown for structure determined by device α8) of nascent polyketide chains 
determined by the devices shown (Table 2)
Table 3  List of devices 
employed in order in natural 
PKS systems that construct 
the polyketide backbone of 
compounds indicated
Structures of compounds except pikromycin are shown in Fig. 1. Methymycin contains the first 6 devices 
shown; pikromycin contains all 7. Devices are from Table 2
NRP non-ribosomal peptide synthetase module
Gene cluster name Devices
Amphotericin α13,β11,β10,γ4,γ3,γ3,γ3,γ3,γ3,γ3,β5,β11,β5,α9,β6,α9,δ4,α9,β6
Borrelidin α1,β6,γ3,γ7,β10,δ6,β6
Chalcomycin α13,β12,γ3,γ3,β15,δ6,β10,α9
Epothilone α13,[NRP],γ7,β6,β20,δ4,δ6,β10,β17,β6
Erythromycin α4,β13,β10,β15,δ6,β10,β10
Fidaxomicin (tiacumicin B) α4,β6,γ7,γ7,β1,γ7,β6,γ2,γ7
Fostriecin α14,γ3,γ2,γ2,β5,β12,γ3,β5,β5
Geldanamycin α5,δ6,δ9,β10,γ7,β18,δ4,γ7
Lipomycin α2,β11,γ7,γ3,γ3,γ3,γ3,α9
Methymycin/pikromycin α14,β13,γ3,β15,δ8,β10,α10
Monensin α13,γ8,δ8,γ3,δ6,γ13,δ3,γ7,δ5,α9,β10,β10,β13
Rapamycin α6,δ6,β6,β15,γ7,β6,β15,δ6,γ3,γ3,γ7,β6,β6,δ6,α9,[NRP]
Rifamycin α5,γ7,α9,β14,γ7,β11,γ7,γ6,γ7,γ3,γ10
Spinosad α14,β5,δ4,β10,β5,γ2,β5,β5,γ7,γ3,γ3
Tacrolimus (FK506) α6,γ7,β13,β6,α7,γ7,δ6,δ9,β19,δ6,α9,[NRP]
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integration systems have been developed and used for het-
erologous polyketide production in Streptomyces [2, 36]. 
Many replicating plasmids, as well as a temperature-sen-
sitive plasmid have been developed into vectors, and meth-
ods to move DNA from E. coli to a variety of Streptomyces 
strains have also been developed [23].
Engineering PKSs
Synthetic biologists use the term refactoring to describe the 
engineering of genes or operons. The modularity of PKSs 
and the similarities of the devices that compose them render 
them as excellent targets for refactoring (at the DNA level) 
to produce novel compounds with predicted structures. Over 
the past 27 years, much work in this area has been under-
taken, mainly employing cis-AT PKS systems. Most efforts 
have been directed at changing the parts within modules 
(AT or reduction domain swapping), deleting modules or 
combining heterologous PKS modules to form novel pol-
yketides. It should be noted that, beyond the development 
of the technology, or the seeking of greater understanding 
of a specific PKS-mediated biochemical step, most of the 
reported efforts have been directed at producing novel antibi-
otics or other polyketides of medical interest. In these cases, 
it generally would not have been possible to predict a priori 
which novel molecules would have the desired properties, 
hence a combinatorial approach, where many compounds 
could be generated simultaneously, would be preferred. 
Because of simple, as well as sophisticated assays for activi-
ties that have been developed for polyketides of interest to 
various pharmaceutical companies, the emphasis has been 
on generating large numbers of novel compounds of diverse 
structure, where low-level production of is usually suffi-
cient for assessment of potential value. Examples include 
the production of derivatives of erythromycin, rapamycin, 
and geldanamycin, among others [28, 35, 47]. Unfortunately, 
the molecular bases of why some engineered PKSs worked 
better than others in these in vivo experiments were gener-
ally not explored.
A less common approach to refactoring modular PKSs, 
and one in which our laboratory is heavily engaged, is to 
produce biofuels and other industrially important chemicals 
as drop-in replacements for currently used petroleum-based 
compounds. In these cases, only a single, or small number 
of novel compounds are targeted for production. Examples 
include adipic acid [16] and short-chain ketones such as 
MEK (2-butanone), and MIBK (4-methyl-2-pentanone) 
[51], which are used as solvents. In general, the monetary 
values of the molecules targeted are low, hence to be com-
petitive with the same compounds resourced from petro-
leum, considerations of product titers, rates of production, 
and yields (relative molar amounts of product to carbon used 
in fermentation) are very important. Here, the emphasis is 
on production levels. Success heavily depends upon precise 
PKS engineering, employing a chassis capable of relatively 
fast growth rates and reaching high densities on inexpensive 
media, as well as possessing all the biochemical precursor 
pathways to support functional expression of heterologous 
PKS systems.
ClusterCAD
We have developed the online database ClusterCAD which 
facilitates the selection of natural cis-AT PKS parts to design 
a novel chimeric PKS that produces a desired small mol-
ecule [11]. ClusterCAD will identify a natural truncated 
PKS with a chemical intermediate most similar to a desired 
target, and can then identify potential donor parts for sub-
sequent domain swaps, which are necessary to produce a 
desired target compound. Currently, ClusterCAD currently 
contains 72 PKS clusters. Notably, among those absent are 
the tacrolimus and salinosporamide PKS clusters.
Here we demonstrate the utility of ClusterCAD to guide 
the selection of PKS parts to produce the novel polyke-
tide target shown in Fig. 5a. First, we use the ClusterCAD 
chemical structure search tool to identify a natural PKS as 
a starting point for engineering. One of the top hits, or most 
chemically similar natural PKSs in ClusterCAD to this target 
molecule is narbonolide, the pikromycin precursor produced 
by the PKS. The ClusterCAD chemical structure search tool 
produces a visual MCS plot (Maximum Common Substruc-
ture) which highlights the shared substructure between the 
query and each hit, as shown in Fig. 5b. As this plot visually 
highlights the similar regions between both structures, it is 
straightforward to identify the following sequence of engi-
neering modifications to the pikromycin PKS, which would 
result in the desired product:
(1) swap the module 0 (load module) acyltransferase 
(AT) domain for an AT which naturally incorporates an 
isobutyryl-CoA substrate; (2) swap the module 1 acyltrans-
ferase (AT) domain for an AT which naturally incorporates 
an ethylmalonyl-CoA substrate; (3) disable the module 5 
ketoreductase (KR); (4) insert a type A1 ketoreductase (KR) 
in module 6; (5) swap the module 6 acyltransferase (AT) 
domain for an AT which naturally incorporates an allylmal-
onyl-CoA substrate.
After decomposing the difference between the natural 
PKS and the target compound into a sequence of engi-
neering modifications as shown above, the ClusterCAD 
sequence search tool can identify suggested donor parts for 
each domain swap, based on amino acid sequence similarity. 
For domain swaps, this is done by searching the sequence 
of each domain for the most similar domain with a desired 
annotation, whereas for domain insertions you can search the 
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entire ‘acceptor’ polypeptide for the most sequence similar 
polypeptide which includes the desired new domain annota-
tions. This produces the following list of top match donor 
parts for the above modifications, in order: (1) Divergolide 
module 6 acyltransferase (AT); (2) Angolamycin module 5 
acyltransferase (AT); (3) Tirandamycin module 1 ketore-
ductase (KR); (4) pikromycin module 5 ketoreductase (KR); 
(5) None, ClusterCAD does not yet contain any PKS clus-
ters which incorporate allylmalonyl-CoA (or ACP). The 
AT domain of module 4 of the tacrolimus PKS specifies 
allylmalonyl-CoA or allylmalonyl-ACP [19, 32].
In summary, this example demonstrates the overall pro-
cess of using ClusterCAD to design a chimeric PKS for 
a novel chemical target, by first identifying a chemically 
similar natural product, and then identifying a set of engi-
neering modifications and donor parts which could, in prin-
ciple yield the desired product. In practice, the rules which 
govern domain swap compatibility, and chimeric junction 
loci remain poorly understood, so it is necessary to test a 
large number of donor parts and junctions to yield an active 
enzyme which produces the desired product at detectable 
levels.
Conclusions
Theoretically, it should be possible to design a polyketide 
of desired structure, write out the list of parts and devices 
required from Tables 1 and 2, respectively (to resemble the 
strategies shown in Table 3 for known PKS systems), employ 
ClusterCAD or similar software to design the devices, syn-
thesize the DNA of the required sequence, introduce the 
DNA into a desired chassis, and express it under a selected 
means of regulation. Except for the production of small 
molecules that are generated from three or fewer modules, 
or the limited engineering of one or two modules within the 
framework of a large PKS, this has not yet been reported. 
Whereas significant progress in our ability to productively 
alter the substrate specificities and reductive outcomes gen-
erated from within a module has taken place over the last 
few years [4], the ability to link modules in sequence to gen-
erate completely new polyketide structures without losing 
biochemical activity is still extremely challenging.
The first issue is the strategy to be employed to cova-
lently link the modules so that there is efficient chain trans-
fer. Small polyketides can be made by covalently assem-
bling two PKS modules into a single polypeptide. It may 
be possible to assemble a larger set of modules into a single 
polypeptide (e.g., nysC has 6 modules in a single polypep-
tide [6]). This approach would obviate the need for docking 
domains to enable correct module–module interactions and 
a few successful examples have been reported in two module 
systems [13, 48]. Since the polypeptide chains of modular 
PKS systems assemble into homodimers [41], it is likely that 
the modules assembled in the long polypeptide will require 
placement of dimerization elements in appropriate posi-
tions if they are not already present [12, 54]. An empirical 
approach appears to be the only way to develop this strategy 
and should be undertaken.
Second, if construction of new PKSs requires the assem-
bly of modules into three or more polypeptides, non-covalent 
intermodular interactions through docking domains may 
be necessary. However, previous efforts showed that more 
than 90% of the hybrid PKSs connected by docking domains 
showed < 10% activities compared to the wild-type coun-
terparts in this approach [24, 29, 30]. It is likely that success 
here will require greater knowledge of the detailed structure 
of not only the docking domains but also of the modules 
O
O
O
OH
O
A B
desired target desired targetnarbonolide
Fig. 5  a Example chemical target used to demonstrate guiding chi-
meric PKS engineering with the ClusterCAD software tool. b A 
maximum common substructure (MCS) plot highlighting the com-
mon regions between the example chemical target (on right), and 
narbonolide, a chemically similar natural PKS found in ClusterCAD 
(on left). The non-highlighted regions represent engineering modifi-
cations necessary to produce the example product
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themselves, and perhaps entire PKS systems. Controlling 
non-covalent intermodular interactions gives the greatest 
opportunity for rapidly generating large numbers of novel 
polyketides, and remains the only means for accomplishing 
this goal combinatorially, which would be a major achieve-
ment in the application of synthetic biology.
Finally, several other issues also need to be addressed 
to generate a working strategy for de novo production of 
novel polyketides. The first is chain passage of the growing 
polyketide chain from the ACP of one module to the cor-
rect KS domain immediately downstream. The accepting KS 
must make proper contact with the donating upstream ACP, 
and must be able to hold the incoming substrate in its active 
site to allow thiotransfer to its active site cysteine. The KS 
must catalyze chain elongation reactions at rates faster than 
its overall kinetics (or lose biochemical activity). Many KS 
domains are known to be somewhat substrate selective for 
both chain length and stereochemistry. It may be possible to 
replace substrate-selective KS domains in each module with 
those that are more substrate flexible (e.g., mycolactone KSs 
[33]), but that means non-cognate intramodular KS–ACP 
interactions for the required chain extensions. Because 
decreased kcat/Km values were previously observed in chain 
elongation with heterologous KS–ACP interfaces [8] and 
chain extension reaction is most likely the rate-limiting step 
in DEBS [22], it is very challenging to solve this issue.
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